Zoetis Inc Stock Price, News & Analysis

Zoetis (NYSE: ZTS) announced that Rob Polzer, EVP and President, Research & Development, will retire at the end of 2025 and leave the company on February 28, 2026, remaining as a scientific advisor through 2026. Zoetis named Kevin Esch, DVM, MPH, PhD, Dipl. ACVP, currently SVP of Global Therapeutics, to succeed Polzer effective January 1, 2026. Esch will join the executive team and report to CEO Kristin Peck.

The release highlights Zoetis’ R&D scale: 17 blockbuster products, more than 2,000 new products and lifecycle innovations in the last 12 years, and an expectation of a significant approval in a major market each year for the next several years. Zoetis will host an Innovation Webcast on December 2, 2025 at 8:30 a.m. ET.

Zoetis (NYSE:ZTS) received European Commission marketing authorization on October 29, 2025 for Portela (relfovetmab), the first monoclonal antibody therapy approved in the EU with a three-month dosing interval to alleviate osteoarthritis (OA) pain in cats. Portela targets nerve growth factor (NGF) and demonstrated effectiveness and tolerability in a nine-month European field trial, including cats with IRIS stage 1–3 kidney disease. The company expects commercial availability in the EU in 2026. Portela expands Zoetis’ feline OA franchise alongside Solensia, which is approved in >40 countries.

Zoetis (NYSE: ZTS) announced the appointment of Stephanie Tilenius to its Board of Directors, effective December 1, 2025. The board will increase from 12 to 13 members on that date. Tilenius brings digital health and AI experience, having served as CEO of Vida Health from 2014 to 2023, founded healthcare companies including a stealth longevity AI firm, and held senior product and commerce roles at Google, PayPal, and eBay.

Zoetis leadership says her background will support the company’s digital transformation and data-driven animal health strategy.

Zoetis (NYSE:ZTS) announced Health Canada approval of Lenivia (izenivetmab) for alleviation of osteoarthritis (OA) pain in dogs. Lenivia is described as the first long-acting canine anti-nerve growth factor monoclonal antibody administered once every three months.

The approval follows a nine-month field study where dogs receiving one injection showed increased mobility and decreased pain. Lenivia targets nerve growth factor (NGF) at a different binding site than existing therapy Librela, aiming to provide longer-lasting pain relief and greater convenience for pet owners.

Zoetis (NYSE: ZTS) announced the EMA CVMP has issued a positive opinion recommending marketing authorization for Lenivia (izenivetmab) to reduce pain from osteoarthritis in dogs.

The European Commission is expected to decide in Q4 2025, and Zoetis anticipates commercial availability in the EU in 2026. Lenivia is a monoclonal antibody that binds a different site on nerve growth factor and is designed to reduce OA pain for three months with one injection. A nine-month field study reported increased mobility and decreased pain after one injection.

Zoetis (NYSE:ZTS) declared a $0.50 per share dividend for the fourth quarter of 2025. The dividend will be paid on December 2, 2025 to holders of record as of the close of business on October 31, 2025.

This provides a scheduled cash return to shareholders for Q4 2025 and specifies the payment and record dates.

Zoetis (NYSE:ZTS) has received conditional FDA approval for Dectomax®-CA1 Injectable, making it the first and only parasite control product approved for preventing and treating New World screwworm (Cochliomyia hominivorax) myiasis in cattle. The approval covers beef cattle, female dairy cattle under 20 months, pregnant beef cows, newborn calves, and bulls.

The treatment provides 21 days of protection against reinfestation. This development is significant as New World screwworm poses a substantial threat to livestock health, with potential economic impacts estimated in the billions of dollars. The product will be available in 250ml and 500ml bottles in the first half of 2026.

Zoetis (NYSE:ZTS), a leading animal health company, has announced it will host a webcast and conference call to discuss its third quarter 2025 financial results on Tuesday, November 4, 2025, at 8:30 a.m. ET.

CEO Kristin Peck and CFO Wetteny Joseph will present the quarterly results and participate in a Q&A session with financial analysts. The webcast will be accessible through Zoetis's investor relations website, with pre-registration now open. A replay will be available after the event.

Zoetis (NYSE:ZTS) has received a positive opinion from the European Medicines Agency's CVMP for Portela® (relfovetmab), a groundbreaking monoclonal antibody therapy for cats with osteoarthritis pain. If approved, Portela will be the first long-acting anti-NGF mAb therapy providing three months of pain relief with a single injection.

The therapy demonstrated strong efficacy in clinical trials and was well-tolerated, including in cats with kidney disease. With up to 40% of cats showing clinical signs of osteoarthritis but only 18% receiving diagnosis, Portela addresses a significant unmet medical need. The European Commission's decision is expected in Q4 2025, with commercial availability planned for 2026.